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The transcription factor GATA2 plays an essential role in the establishment and maintenance of adult hematopoiesis. It
is expressed in hematopoietic stem cells, as well as the cells that make up the aortic vasculature, namely aortic
endothelial cells and smooth muscle cells. We have shown that GATA2 expression is predictive of location within the
thoracic aorta; location is suggested to be a surrogate for disease susceptibility. The GATA2 gene maps beneath the
Chromosome 3q linkage peak from our family-based sample set (GENECARD) study of early-onset coronary artery
disease. Given these observations, we investigated the relationship of several known and novel polymorphisms within
GATA2 to coronary artery disease. We identified five single nucleotide polymorphisms that were significantly
associated with early-onset coronary artery disease in GENECARD. These results were validated by identifying
significant association of two of these single nucleotide polymorphisms in an independent case-control sample set that
was phenotypically similar to the GENECARD families. These observations identify GATA2 as a novel susceptibility gene
for coronary artery disease and suggest that the study of this transcription factor and its downstream targets may
uncover a regulatory network important for coronary artery disease inheritance.
Citation: Connelly JJ, Wang T, Cox JE, Haynes C, Wang L, et al. (2006) GATA2 is associated with familial early-onset coronary artery disease. PLoS Genet 2(8): e139. DOI: 10.
1371/journal.pgen.0020139
Introduction
Coronary artery disease (CAD) is the most common form of
heart disease in the Western world. It affects more than 13
million Americans and is one of the leading causes of death in
the United States [1]. CAD is a complex genetic disease;
despite substantial evidence of a genetic contribution for
CAD and its risk factors [2–10], the mode of inheritance does
not follow Mendelian segregation. Complex genetic diseases
are considered multifactorial in that they are characterized
by the inheritance of multiple genetic variants acting in
concert with environmental effects to promote the disease
state.
Despite the obvious importance of environmental and
behavioral risk factors, evidence of the genetic contribution
to CAD is strong and consistent. The estimated relative risk of
developing early-onset CAD in a ﬁrst-degree relative is
between 3.8 and 12.1, depending on the age of onset (AOO)
of the proband, and higher risk correlates with earlier AOO
[2,10]. Additionally, data from the Framingham Heart Study
have shown an increased risk of incident cardiovascular
disease in both age-sex–adjusted models (odds ratio [OR] ¼
1.55) and models adjusted for cardiovascular risk factors (OR
¼ 1.45) for siblings of affected individuals [4].
Ten separate linkage screens have been performed in CAD
sample sets to identify candidate genes that contribute to the
genetic etiology of CAD, including our own GENECARD
study [11]. Cumulatively, these screens have identiﬁed regions
of linkage on Chromosomes 1, 2, 3, 4, 5, 7, 12, 13, 14, 16, 17,
19, and X [11–20], with genetic regions on 3q26–27 and 2q34–
37 displaying cross-study CAD susceptibility [21]. Addition-
ally, a recent genome screen by Bowden et al. [20] identiﬁed
linkage to Chromosome 3q13 in a type 2 diabetes population
subset by self-reported and clinically assessed CAD (The
Diabetes Heart Study). This region is nearly identical to the
Chromosome 3q13 linkage identiﬁed in the GENECARD
study. Though a collection of CAD genetic regions have been
identiﬁed, only a single gene mapping to Chromosome 13q,
ALOX5AP, has been shown to contain variants that reprodu-
cibly predispose individuals to myocardial infarction, a
speciﬁc manifestation of the cardiovascular disease pheno-
type [15,22–24].
Our goal is to characterize the underlying genetic
mechanisms involved in the development of CAD. Through
convergent analyses of linkage and expression data, we have
identiﬁed the transcription factor GATA2 as having an
increased potential to be involved with CAD susceptibility.
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linkage study that sampled a cohort of families with at least
two siblings with early-onset CAD (AOO in men ,51 y and
women ,56 y) [25]. The most signiﬁcant region of linkage, of
the several regions that were identiﬁed [11], was localized to
Chromosome 3q13 (multipoint log of the odds [LOD]¼3.50).
GATA2 maps beneath the one-LOD down support interval for
this linkage peak on Chromosome 3.
We also utilized gene expression patterns from Seo et al.
[26] that identiﬁed GATA2 as one of the genes most predictive
of the location within human donor aortas. Given that
atherosclerotic disease has been shown to display increasing
severity from proximal to distal locations within the aorta
[27], these investigators theorized that differences in regional
expression patterns within the aorta could be related to
disease susceptibility.
Given the convergence of the results, we hypothesized that
GATA2 may represent a newly identiﬁed susceptibility gene
for CAD. Therefore, we investigated the haplotype structure
of GATA2 to identify single nucleotide polymorphisms (SNPs)
for genotyping within the gene in order to test the hypothesis
that GATA2 is associated with CAD. We identiﬁed association
in both a family-based sample (GENECARD) and in a
validation dataset of nonfamilial CAD (CATHGEN). The
results identify GATA2 as a novel CAD susceptibility gene and
suggest that the study of this transcription factor and its
downstream targets may undercover a regulatory network
important for CAD.
Results
GATA2 SNP Selection and Genotyping
HapMap (http://www.hapmap.org) and Perlegen (http://
genome.perlegen.com) databases were used to identify known
SNPs within the GATA2 gene and 3,000 base pairs both
upstream and downstream of the gene to account for putative
promoter and downstream regulatory elements. A total of 12
SNPs were identiﬁed with a minor allele frequency (MAF)
.10% in the Caucasian population (white Americans of
European descent). LDSelect [28], which is used by SNPse-
lector [29], determined that these 12 SNPs, using an r
2 ¼ 0.7,
represent 12 linkage disequilibrium (LD) bins. All SNPs, with
the exception of rs1806462, were genotyped in our GENE-
CARD sample set (Figure 1, LD bin SNPs are black).
Concurrently, we sought to determine whether additional
coding SNPs within GATA2 could be identiﬁed. We se-
quenced each of the six GATA2 exons using a Caucasian
sample consisting of 16 affected individuals and 16 individ-
uals of unknown status. Five novel SNPs were identiﬁed
within the 39 untranslated region of the gene, whereas three
previously validated SNPs were identiﬁed and two additional
SNPs, which did not have a validated status in dbSNP
(rs11708606 and rs10934857), were validated by our novel
sequence (Table 1). We included rs10934857 in our analysis
because LD calculations using the sequenced individuals
suggested that this SNP may reside in a separate bin. The
location of the ﬁve novel SNPs in relation to the 12 selected
SNPs for our association studies is shown in Figure 1 (novel
SNPs are grey). All 17 SNPs were genotyped in our association
studies.
Single-Marker Family-Based Association in GENECARD
Genotyping was performed on the 12 a priori SNPs and the
ﬁve novel SNPs in the GENECARD sample, which represents
both the original genome linkage screen families as well as the
follow-up collection set (Table 2, n ¼ 1,101 families). The
Figure 1. Schematic of the GATA2 Gene Structure
The 12 SNPs representing predicted LD bins in GATA2 are shown in black; the five novel SNPs identified through sequencing are shown in grey.
 and *
indicate a synonymous and nonsynonymous SNP, respectively.
DOI: 10.1371/journal.pgen.0020139.g001
PLoS Genetics | www.plosgenetics.org August 2006 | Volume 2 | Issue 8 | e139 1266
GATA2 and Coronary Artery Disease
Synopsis
Coronary artery disease (CAD) is the most common form of heart
disease in the Western world and is one of the leading causes of
death in the United States. CAD is inherited and is a complex genetic
disease because it results from changes to multiple genes acting in
concert with one another and the environment. The authors locate
CAD susceptibility genes by convergence of techniques and identify
variation within a gene of interest in an early-onset CAD population.
If a specific variant is found more often in affected individuals or
families than in controls, this can suggest that this gene variant is
associated with disease. The authors have identified a gene, GATA2,
which is located in a genomic region suspected to contain genes for
CAD and displays expression patterns predictive of location of
disease within human donor aortas. They have identified several
GATA2 variants that segregate with CAD in a family-based early-
onset CAD population and have further validated two of these
associations in a separate young case-control sample affected with
CAD. These data imply that the transcription factor GATA2 may play
a role in CAD susceptibility and suggest that the study of GATA2
targets may uncover a set of GATA2-regulated genes important to
CAD inheritance.characteristics of this study group are deﬁned in Tables 2 and
3 and elsewhere [11,25]. Pairwise LD between each SNP was
measured using the Graphical Overview of Linkage Disequi-
librium package separately in both Caucasian affected
(GENECARD probands with unaffected siblings) and un-
affected (proband matched unaffected) individuals; no
signiﬁcant differences were seen between these two groups
(unpublished data). We examined the LD structure of GATA2
in order to assess the quality of our tagSNP selection. The
Haploview plot of these data in the unaffected Caucasian
population (Figure 2) shows a weak block of LD in the 59 end
of the gene. The lack of haplotype block structure from our
analysis was expected because of the prior selection of
nonredundant haplotype tagging SNPs.
We employed the test for association in the presence of
linkage (APL) to conduct association analysis at markers in
GATA2 in order to make use of the large number of affected
sibling pairs in the GENECARD sample, as well as to
appropriately infer missing parental genotypes and to
account for the correlation between transmission of parental
marker alleles to multiple affected offspring due to linkage
[30]. APL analysis of the 17 GATA2 SNPs identiﬁed ﬁve
signiﬁcant associations (p , 0.05) with early-onset CAD
(Table 4, highlighted in red). Four of the ﬁve associated SNPs
are located in the distal end of GATA2, encompassing intron
5, exon 6, and a region downstream of the gene. Two of these
SNPs are in moderate LD with one another, rs2713604 and
rs2713579 (r
2 ¼ 0.85). We noted that none of these SNPs
would withstand the stringent Bonferroni correction for
multiple comparisons (a ¼ 0.05, n ¼ 17, p   0.003). Addition-
ally, we assessed evidence for linkage to the Chromosome 3
region in the additional GENECARD families from the
follow-up collection. The multipoint LOD scores for the
GATA2 region including the ﬂanking microsatellites are zero.
The largest two-point result in the second GENECARD
population is 0.39 for rs2335052. Thus, there appears to be
no strong and consistent evidence for linkage as we observed
in the initial genome screen families.
Haplotype Analysis of GATA2 SNPs in GENECARD
We have identiﬁed a region of association with CAD within
the 39 end of GATA2, which encompasses four SNPs. In order
to more accurately identify the SNP(s) associated with early-
onset CAD, we used the APL test to calculate the transmission
frequencies of all possible haplotypes for pairwise combina-
tions of the 17 SNP markers within GATA2 in the GENECARD
sample. These frequencies were compared in a global test
accounting for rare haplotypes [30] (Table S1). We observed
six pairwise haplotypes of the 171 comparisons made, which
involved seven SNPs with little to no LD (0.02 , r
2 , 0.28)
with remarkably strong associations (Table 5). These six pairs
maintained strong association after Bonferroni correction,
with rs2713604_rs3803 and rs3803_rs2713594 exhibiting
the strongest association (global Bonferroni corrected p ,
0.0012 for both).
The pairwise haplotype results suggest that these haplo-
types may be extended to include additional SNPs. We
identiﬁed a single three-SNP haplotype and an independent
four-SNP haplotype using the strongly associated haplotype
pairs that shared a common SNP. These haplotypes were
examined using the APL test. Both of these haplotypes were
overtransmitted in GENECARD families (Table 5). We were
not able to analyze the full seven SNP haplotypes in family-
based APL analysis.
Replicating Single-Marker Association of GATA2 SNPs in
CATHGEN Case-Control Sample
We identiﬁed ﬁve SNPs within GATA2, as well as six
pairwise haplotypes and a single three-SNP and four-SNP
haplotype that are signiﬁcantly associated with early-onset
Table 1. SNPs Identified by Sequencing the Six Exons of GATA2 in 32 Individuals Including Five Novel GATA2 SNPs
SNP Gene Location Coding Change NCBI35 bp Location Alleles
a MAF (%)
RS1573858 Exon 2 P5P 129688558 G/C 32.8
RS2335052 Exon 3 A164T 129687649 G/A 9.4
RS11708606 Intron 4 — 129683504 C/T 20.3
RS10934857 Exon 6 39 UTR 129682360 C/T 23.4
RS3803 Exon 6 39 UTR 129682078 C/T 20.3
3P0455
b Exon 6 39 UTR 129682377 C/T 1.6
3P0450
b Exon 6 39 UTR 129682150 C/T 1.6
3P0448
b Exon 6 39 UTR 129682014 C/T 3.1
3P0456
b Exon 6 39 UTR 129681863 C/T 1.6
3P0457
b Exon 6 39 UTR 129681678 T/A 3.1
aMajor/minor allele; coding changes are defined by amino acid and location or by region within transcript.
bNovel SNP.
DOI: 10.1371/journal.pgen.0020139.t001
Table 2. GENECARD Sample Size
Sample Initial Genome
Screen Families
Follow-Up
Collection
All
Families
Number of families 420 681 1,101
Individuals sampled 1,129 1,825 2,954
Affected individuals 1,005 1,255 2,260
Unaffected individuals 122 481 603
Unaffected .age 60 y (M);
65 y (F)
84 192 276
Affected sibling pairs 539 427 966
Discordant sibling pairs 169 467 825
Discordant sibling pairs
.60 y (M); 65 y (F)
45 56 137
Parent–child trios 42 35 77
DOI: 10.1371/journal.pgen.0020139.t002
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study criteria (see Materials and Methods) from the CATH-
GEN study to validate these results in a phenotypically
similar, nonfamilial young affected CAD case-control cohort.
Baseline clinical characteristics in GENECARD probands (n¼
1,101) and CATHGEN participants and unaffected controls
are presented in Table 3. We genotyped the ﬁve SNPs
signiﬁcantly associated with disease status and the additional
four SNPs that were identiﬁed in the haplotype analysis, in
the CATHGEN cases and controls. Allelic association was
examined using a multivariable logistic regression analysis. In
order to test for a true genetic effect, we adjusted for race and
sex or race, sex, and known CAD risk factors (see Materials
and Methods). We identiﬁed signiﬁcant associations in two of
the ﬁve SNPs, rs2713604 and rs3803 (Table 6), with stronger
association identiﬁed in the race, sex, and CAD risk factor–
Figure 2. Pairwise LD between GATA2 SNPs
LD was estimated in one unaffected Caucasian individual from each nonredundant GENECARD discordant sibling pair (n¼279). A similar pattern of LD
was observed using the matched probands.
DOI: 10.1371/journal.pgen.0020139.g002
Table 3. Clinical Characteristics of GENECARD Probands and CATHGEN Participants
Category Characteristic GENECARD Probands CATHGEN Participants Unaffected Controls
(n ¼ 1,101) (n ¼ 656) (n ¼ 410)
Mean age of onset (SD) 43.9 (5.7)
a 46.4 (6.3) N/A
Race
b Caucasian 89.0%
a 71.3% 75.2%
African American 5.3%
a 22.0% 19.9%
American Indian 4.0%
a 5.4% 3.6%
Asian 0.5%
a N/A N/A
Other (unknown) 1.3% 1.2% 1.3%
Sex Male 70.8%
a 79.2%
a 42.9%
Family history of CAD 100.0%
a 54.6%
a 26.3%
Body mass index, kg/m
2 (SD) 30.8 (6.9) 30.7 (6.4)
a 29.1 (7.0)
Ever smoked 78.3%
a 69.1%
a 40.0%
History of diabetes 22.9%
a 33.3%
a 21.0%
History of hypertension 59.4%
a 69.6% 67.1%
History of myocardial infarction 65.4%
a 52.1%
a N/A
History of coronary artery bypass graft 48.2%
a 39.7%
a N/A
Mean systolic blood pressure, mm Hg (SD) 128.9 (20.4)
a 140.5 (24.3)
a 149.9 (23.6)
Mean diastolic blood pressure, mm Hg (SD) 77.3 (12.5) 78.3 (14.1) 77.2 (13.6)
Total cholesterol, mg/dl (SD) 212.3 (85.1)
a 192.9 (62.2) 191.5 (48.7)
Low-density lipoprotein, mg/dl (SD) 116.8 (87.4) 109.8 (43.2) 107.0 (35.8)
High-density lipoprotein, mg/dl (SD) 35.2 (36.7)
a 40.5 (12.2)
a 52.3 (18.4)
Triglycerides, mg/dl (SD) 216.6 (284.6) 222.8 (260.8)
a 156.8 (125.5)
aSignificant difference (p , 0.05) between GENECARD probands and CATHGEN cases or CATHGEN cases and controls. Differences between the two groups were determined using a chi-
square test (categorical variables) or a t-test (numerical variables).
bSelf reported.
SD, standard deviation; N/A, not applicable.
DOI: 10.1371/journal.pgen.0020139.t003
PLoS Genetics | www.plosgenetics.org August 2006 | Volume 2 | Issue 8 | e139 1268
GATA2 and Coronary Artery Diseaseadjusted model (compare Table 6 and Table S2). Moreover,
we identiﬁed the minor allele of rs2713604 as a risk allele (OR
¼ 1.52, 95% conﬁdence interval [CI] ¼ 1.10 to 2.09) and the
minor allele of rs3803 as a protective allele (OR ¼ 0.69, 95%
CI ¼ 0.50 to 0.96). In order to conﬁrm the direction of the
association of these two alleles in GENECARD, we compared
the GENECARD probands from the United States to the
CATHGEN controls. We veriﬁed that the allele frequencies
are similar to those observed for the CATHGEN cases (Table
S3); in addition, we observed similar odds ratios, though
rs2713604 is not signiﬁcant.
Haplotype Analysis in CATHGEN
The six signiﬁcant pairwise haplotypes from the GENE-
CARD analysis suggest that these haplotypes may be
important in deﬁning CAD risk; we performed haplotype
analysis in the CATHGEN population. We examined the six
signiﬁcant pairwise haplotypes from GENECARD in the
CATHGEN population and identiﬁed three signiﬁcant (p ,
0.05) pairs (Table 5). We expanded our analysis to include the
three-SNP haplotype, the four-SNP haplotype, and the
complete seven-SNP haplotype suggested by the GENECARD
sample, with global p-values of 0.16, 0.05, and 0.26, respec-
tively (Table 5).
We were intrigued by the most signiﬁcant haplotype in
GENECARD and CATHGEN, rs2713604_rs3803, because the
results from the logistic regression suggested that the minor
allele of rs2713604 conferred risk, whereas the minor allele of
rs3803 was protective. Upon further analysis, we discovered
that the rs2713604_T_rs3803_A haplotype (risk_protec-
tive), which is predicted to occur at 6.5% in the population,
does not exist in either of our populations. Although the LD
as measured by r
2 is low, the D9 value is nearly 1, reﬂecting the
complete absence of the haplotype involving the associated
alleles at markers rs2713604 and rs3803 (Table S4). The two-
locus genotypes conﬁrm that this haplotype is not observed in
our data. Additionally, the absence of these genotype
combinations makes the statistical analysis of possible multi-
locus or interaction effects nearly impossible.
Discussion
We identiﬁed a transcription factor, GATA2,t h r o u g h
convergent analysis of linkage and expression data in an effort
to deﬁne the underlying molecular mechanisms that lead to
CAD. Genotyping and subsequent analysis of GATA2 tagging
and novel SNPs in a family-based early-onset CAD sample
identiﬁed ﬁve SNPs signiﬁcantly associated with early-onset
CAD. We validated the association of two of these SNPs,
rs2713604 and rs3803, in an independent case-control dataset,
as well as the direction of the association, thus identifying
GATA2 as a susceptibility gene candidate for early-onset CAD.
Thedatasuggestthatpolymorphismsinthe39endofGATA2
may increase susceptibility to developing CAD. We identiﬁed
several novel SNPs within the sixth exon of GATA2 but did not
identifyassociationwithearly-onset CADorLD between these
SNPs and SNPs that were found to be associated with early-
onset CAD. Although the functional relevance of our two most
signiﬁcantly associated SNPs remains unknown, one of these
SNPs, rs3803, is conserved between multiple species (human,
mouse, rat, and dog) and lies near one of three known
Table 5. Haplotype Analysis Identifies Significant Haplotypes Associated with Early-Onset CAD
SNP Combination GENECARD CATHGEN
Global p-Value Global p-Value
a
RS6439129_3P0448 0.00019 0.34700
RS2713604_RS10934857 0.00002 0.05717
RS2713604_RS3803 0.00001 0.01747
RS10934857_RS2713594 0.00020 0.02059
RS3803_RS2713594 0.00001 0.02709
3P0448_RS2713579 0.00008 0.16458
RS6439129_3P0448_RS2713579 0.00094 0.15739
RS2713604_RS10934857_RS3803_RS2713594 0.00679 0.05129
RS6439129_3P0448_RS2713604_RS10934857_RS3803_RS2713579_RS2713594 ND 0.26264
p-Values  0.05 are indicated in red.
aAdjustments made for race, sex, and history of hypertension, history of diabetes mellitus, body mass index, history of dyslipidemia, and smoking history.
ND, not done.
DOI: 10.1371/journal.pgen.0020139.t005
Table 4. GATA2 SNPs Are Associated with Early-Onset CAD in
GENECARD
SNP NCBI35 bp Location p-Value
a Variance
RS6439129 129695471 0.313 98.03
RS9851497 129695224 0.499 94.09
RS2860228 129692365 0.697 110.15
RS1573858 129688558 0.551 107.36
RS2335052 129687649 0.019 98.51
RS2659689 129685704 0.205 100.27
RS2713603 129683232 0.261 105.96
RS2713604 129683157 0.005 97.56
3P0455 129682377 0.022 2.47
RS10934857 129682360 0.069 114.20
3P0450 129682150 0.653 13.81
RS3803 129682078 0.025 107.52
3P0448 129682014 0.745 36.17
3P0456 129681863 0.914 0.57
3P0457 129681678 0.548 29.02
RS2713579 129680802 0.004 106.48
RS2713594 129679198 0.109 126.21
p-Values  0.05 are indicated in red.
aAssociation in the Presence of Linkage (APL) test.
DOI: 10.1371/journal.pgen.0020139.t004
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GATA2 and Coronary Artery Diseasepolyadenylation sites [31,32]. We are currently investigating
whether any of these polymorphisms control tissue-speciﬁc
polyadenylation of this transcript.
We searched for haplotypes associated with disease using
the GENECARD and CATHGEN cohorts. We identiﬁed
several pairwise haplotypes in GENECARD, three of which
were signiﬁcant in CATHGEN; however, we were unable to
identify a single consistent haplotype combination when we
expanded these haplotypes to include four SNPs. There are at
least three possible explanations for these results. The
analysis in the CATHGEN group may be underpowered
when additional markers are added to the haplotypes, thus
creating additional rare haplotypes. There may also be an
ungenotyped SNP in weak LD with both haplotype sets, which
would explain the ﬁnding of association with two separate
sets of SNPs. A third explanation for these ﬁndings is that
there is no single haplotype underlying the increased risk for
CAD, but rather there are multiple SNPs and potentially
multiple independent haplotypes. A larger sample size and
additional genotyping will be required to evaluate these
scenarios. Although the haplotype results do not point to a
consistent risk haplotype within the GATA2 gene, taken
together our results identify nucleotide variants within
GATA2 as a risk factor of early-onset CAD.
One of the more difﬁcult aspects of genetic association
analysis is the appropriate multiple comparison correction of
the statistical signiﬁcance of any given result. These correc-
tions range from the most conservative Bonferroni correc-
tion, to false discovery rate approaches [33], to weighted
corrections of combined data, to no correction at all. In our
case we report uncorrected p-values; however, it should be
noted that the results for the haplotype analysis would, in
fact, survive a Bonferroni correction. We base our enthusiasm
for GATA2 as a gene implicated in CAD susceptibility because
we identiﬁed two separate signiﬁcant markers in low LD in
two independent populations. We believe that it is highly
likely that they constitute two important independent
markers for two reasons: they are physically linked within
the same gene and in the same part of the gene and are
signiﬁcantly associated with disease in two independent
populations. Further work to elucidate the function of
GATA2 in CAD, including the CAD-associated polymor-
phisms and its downstream targets, is necessary in order to
begin to understand the role this transcription factor plays in
this disease.
Genetic and phenotypic heterogeneity are features of
complex disease, particularly CAD. The pathobiology of
CAD itself is sufﬁciently intricate in that the core of the
disease is the formation of the atherosclerotic plaque. The
pathways that are involved in lesion predisposition, forma-
tion, and disruption are numerous and can be modulated by
the environment and other underlying genetic diseases (for
example, diabetes or lipid disorders), as reviewed by Watkins
and Farrall [34]. Additionally, the lack of a consistent clinical
deﬁnition of CAD across studies further confounds genetic
analysis. The detection of multiple, signiﬁcant but non-
overlapping chromosomal regions in ten genome screens is
an indicator of the mixed genetic and phenotypic character-
istics of this disease. We are encouraged by the recent data of
Bowden et al. [20] that suggest a replication of the
Chromosome 3q13 linkage evidence we initially reported,
though phenotypic heterogeneity still remains. We also see
evidence of this heterogeneity in our own dataset, both
phenotypic [35] and in the linkage scores. We failed to detect
evidence for linkage on Chromosome 3 in our follow-up
dataset (maximum multipoint LOD score ¼ 0.0 at GATA2),
and though the result may be discouraging, the result is not
surprising given the observed heterogeneity of linkage
evidence across the ten previously published genome screens.
Despite the evident heterogeneity in our CAD population, we
detected an association signal with SNPs in GATA2 in two
separate CAD datasets. We suggest that our validation of
GATA2 warrants further study in our datasets, including an
expansion to other racial groups such as Asians and African
Americans, as well as in other studies to understand what role
GATA2 might play in CAD development.
The results of our study are important for three main
reasons. First, GATA2 is a transcription factor that is
indispensable for all hematopoiesis [36]. It is essential for
the development and differentiation of hematopoietic stem
and progenitor cells [36–38]. It is expressed both in
endothelial cells [37] and smooth muscle cells (J. Connelly,
unpublished data), the two primary cell types comprising the
aorta. It has been shown to regulate EDN1 transcription, a
potent vasoconstrictor that is expressed only in endothelial
cells [39]. It is also known to regulate several other
Table 6. Replication of GATA2 SNPs Associated with Early-Onset CAD in the CATHGEN Case-Control Sample Set
SNP Location (bp) Minor Controls Cases Allele Odds Ratio Genotype Odds Ratio
Allele MAF (%) MAF (%) p-Value
a (95% CI) p-Value
a (95% CI)
RS6439129 129695471 A 31.8 32.6 0.126 1.3 (0.9, 1.8) 0.174 1.2 (0.9, 1.5)
RS2335052 12687649 A 14.5 16.1 0.560 1.1 (0.8, 1.6) 0.686 1.1 (0.8, 1.5)
RS2713604 129683157 T 30.5 33.3 0.011 1.5 (1.1, 2.1) 0.029 1.3 (1.0, 1.7)
3P0455 129682377 T 0.4 0.4 0.710 0.7 (0.2, 3.6) 0.710 0.7 (0.2, 3.6)
RS10934857 129682360 T 27.1 25.0 0.062 0.7 (0.5, 1.0) 0.093 0.8 (0.6, 1.0)
RS3803 129682078 A 21.8 19.2 0.028 0.7 (0.5, 1.0) 0.052 0.8 (0.6, 1.0)
3P0448 129682014 A 2.2 3.3 0.319 1.5 (0.7, 3.0) 0.270 1.5 (0.7, 3.0)
RS2713579 129680802 G 31.6 33.0 0.164 1.3 (0.9, 1.7) 0.208 1.2 (0.9, 1.5)
RS2713594 129679198 A 43.4 43.1 0.659 0.9 (0.7, 1.3) 0.919 1.0 (0.8, 1.3)
p-Values  0.05 are indicated in red.
aAdjustments made for race, sex, and history of hypertension, history of diabetes mellitus, body mass index, history of dyslipidemia, and smoking history.
bp, base pair, NCBI35; CI, confidence interval; MAF, minor allele frequency.
DOI: 10.1371/journal.pgen.0020139.t006
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GATA2 and Coronary Artery Diseaseendothelial-speciﬁc genes, namely NOS3 [40], VWF [41], KDR
[42], and PECAM1 [43], each of which can be linked to CAD
[44–50]. The role GATA2 plays in hematopoiesis and
endothelial cell function suggests that GATA2 may partic-
ipate in endothelial progenitor cell potential and, thus,
vascular disease propensity [51–55]. The effect of the CAD-
associated polymorphisms on GATA2 function still remains
to be elucidated. However, our data suggest that GATA2 may
be functionally involved in the pathophysiology of CAD.
Second, our study results are important because of the
strength of identifying signiﬁcant associations with complex
disease arising from a hypothesis-driven experimental design.
We identiﬁed and genotyped tagging SNPs in a candidate
gene that was identiﬁed through ‘‘genomic convergence’’ [56],
a convergence of multiple lines of evidence. We used a family-
based sample set that is heavily laden with a genetic burden
for CAD, as well as a test of association (APL) that allows us to
make full use of the GENECARD population while accounting
for linkage. We selected a phenotypically similar case-control
dataset to validate the GATA2 association we observed in
GENECARD, which allowed us to identify two strong and
separate associations with CAD. The use of convergence for
candidate gene selection coupled with the thorough coverage
of LD across a gene has allowed us to identify two
signiﬁcantly associated SNPs in two independent early-onset
CAD samples.
Third, two other transcription factors have been impli-
cated in cardiovascular phenotypes, MEF2A (myocardial
infarction) [57–59] and USF1 (lipid traits) [60–62]. Complex
genetic diseases, such as cardiovascular disease, are most
likely the result of an accumulation of multiple small genetic
changes that inﬂuence an individual’s ability to cope with
biological and environmental effects. Transcription factors
(and their cognate binding sites), which ultimately inﬂuence
the expression of many downstream genes, may be important
targets to characterize when considering how small genetic
changes can inﬂuence multiple genetic outcomes. Slight
changes to the level of a transcription factor in the cell can
have a dramatic effect on the downstream targets of these
factors. Hence, these types of genes will most likely be
important in the dissection of complex human disease.
Our work suggests that common variants within GATA2
play a role in CAD, an important complex genetic disease.
Identiﬁcation of a transcription factor associated with CAD
in two separate samples implies that GATA2-regulated genes
may play a very signiﬁcant role in CAD susceptibility and
progression. These GATA2 target genes, which remain to be
explored in this context, represent a rich set of candidate
genes from which to dissect genetic contributions to coronary
disease susceptibility.
Materials and Methods
Early-onset CAD family-based sample (GENECARD). GENECARD
is a collaborative study involving investigators afﬁliated with the
Duke Center for Human Genetics, the Duke University Center for
Living, the Duke Clinical Research Institute, the Duke University
Consortium for Cardiovascular Studies, and additional investigative
sites of the GENECARD Study Network. The study is coordinated at
Duke and located throughout ﬁve other international sites, and the
study design has been previously reported [25]. In brief, collection of
families began in March 1998 and was completed on 31 March, 2002.
All study participants signed a consent form approved by the
responsible institutional review board or local ethics committee.
The sample set used for the initial genome-wide linkage screen
within the GENECARD project was composed of 493 affected sibling
pairs in 420 families, where at least two siblings met the criteria for
early-onset CAD. The characteristics of this study group are
summarized in Table 2 and elsewhere [11,25]. We have expanded
our collection to include an additional 681 families together with a
large number of unaffected participants from all families. Un-
affected participants were deﬁned as siblings and relatives who have
not been diagnosed with CAD and are older than 55 y of age (males)
or older than 60 y of age (females). This additional collection has
increased our sample size to 2,954 affected and unaffected
individuals (Table 2).
Early-onset CAD case-control sample (CATHGEN). CATHGEN
participants were recruited sequentially through the cardiac cathe-
terization laboratories at Duke University Hospital (Durham, North
Carolina, United States) with approval from the Duke Institutional
Review Board. All participants undergoing catheterization were
offered participation in the study and signed informed consent.
Medical history and clinical data were collected and stored in the
Duke Information System for Cardiovascular Care database main-
tained at the Duke Clinical Research Institute [63].
Controls and cases were chosen on the basis of extent of CAD as
measured by the CAD index (CADi). CADi is a numerical summary
of coronary angiographic data that incorporate the extent and
anatomical distribution of coronary disease [64]. CADi has been
shown to be a better predictor of clinical outcome than extent of
CAD [65]. Affected status was determined by the presence of
signiﬁcant CAD deﬁned as a CADi   32 [66]. For patients older than
55 y of age, a higher CADi threshold (CADi   74) was used to adjust
for the higher baseline extent of CAD in this group. Medical records
were reviewed to determine the AOO of CAD, i.e., the age at ﬁrst
documented surgical or percutaneous coronary revascularization
procedure, myocardial infarction, or cardiac catheterization meet-
ing the above-deﬁned CADi thresholds. The CATHGEN cases were
stratiﬁed into a young affected group (AOO   55 y), which provides
a consistent comparison for the GENECARD family study. Controls
were deﬁned as  60 y of age, with no CAD as demonstrated by
coronary angiography and no documented history of cerebrovas-
cular or peripheral vascular disease, myocardial infarction, or
interventional coronary revascularization procedures. A comparison
of clinical characteristics between GENECARD and CATHGEN
probands and unaffected CATHGEN controls is presented in
Table 3.
Novel SNP detection by GATA2 re-sequencing. GATA2 exons (six in
total) were PCR ampliﬁed using standard conditions and sequenced
using ABI Big Dye v3.1 and an ABI 3730 automated sequencer.
Sequencing data were analyzed using Sequencher software (Gene
Codes, Ann Arbor, Michigan, United States). All sequence amplicons
were generated within 16 GENECARD affected individuals and 16
randomly ascertained individuals of unknown status. DNA derived
from the blood of 17 Caucasian males and 15 Caucasian females was
used for novel SNP discovery.
SNP genotyping. A minimal set of tagging SNPs with an MAF of
.10% [28] was selected for genotyping in the GENECARD and
CATHGEN samples to cover the predicted LD structure in GATA2
(;14 kilobases) using the SNPselector program [29]. Additionally, ﬁve
novel GATA2 SNPs identiﬁed by de novo sequencing were also
genotyped in the GENECARD and CATHGEN collections. Genomic
DNA for the GENECARD and CATHGEN samples was extracted from
whole blood using the PureGene system (Gentra Systems, Minneap-
olis, Minnesota, United States). Genotyping in GENECARD was
performed using the ABI 7900HT Taqman SNP genotyping system
(Applied Biosystems, Foster City, California, United States), which
incorporates a standard PCR-based, dual ﬂuor, allelic discrimination
assay in a 384-well–plate format with a dual laser scanner. Allelic
discrimination assays were purchased through Applied Biosystems,
or, if the assays were not available, primer and probe sets were
designed and purchased through Integrated DNA Technologies
(Coralville, Iowa, United States). A total of 15 quality control
samples—composed of six reference genotype controls in duplicate,
two Centre d’Etude du Polymorphisme Humain pedigree individuals,
and one no-template sample—were included in each quadrant of the
384-well plate. Genotyping in CATHGEN was performed using the
Illumina BeadStation 500G SNP genotyping system (Illumina, San
Diego, California, United States). Each Sentrix Array generates 1,536
genotypes for 96 individuals; within each individual array experi-
ment, four quality control samples were included, two Centre d’Etude
du Polymorphisme Humain pedigree individuals and two identical
in-plate controls. Results of the Centre d’Etude du Polymorphisme
Humain and quality-control samples were compared to identify
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SNPs that showed mismatches on quality-control samples were
reviewed by an independent genotyping supervisor for potential
genotyping errors. All SNPs examined were successfully genotyped
for 95% or more of the individuals in the study. Error rate estimates
for SNPs meeting the quality control benchmarks were determined to
be less than 0.2%.
Statistical analysis. All SNPs were tested for deviations from
Hardy-Weinberg equilibrium in the affected and unaffected race-
stratiﬁed groups. No such deviations were observed. Additionally, LD
between pairs of SNPs was assessed using the Graphical Overview of
Linkage Disequilibrium package [67] and displayed using Haploview
[68]. Family-based association was tested using the APL test [30]. The
APL test incorporates data from affected sibling pairs with available
parental data and unaffected siblings in the analyses, effectively using
all available information in the GENECARD families. The APL
software appropriately accounts for the non-independence of
affected siblings and calculates a robust estimate of the variance.
APL results from markers with variance estimates of less than ﬁve are
viewed as less reliable [69]. Allelic association in CATHGEN and the
GENECARD probands from the United States was examined using
multivariable logistic regression modeling adjusted for race and sex,
and also for race, sex, and known CAD risk factors (history of
hypertension, history of diabetes mellitus, body mass index, history of
dyslipidemia, and smoking history) as covariates. These adjustments
could hypothetically allow us to control for competing genetic
pathways that are independent risk factors for CAD, thereby allowing
us to detect a separate CAD genetic effect. SAS 9.1 (SAS Institute,
Cary, North Carolina, United States) was used for statistical analysis.
APL software was used to identify haplotypes in GENECARD. The
HaploStats package was used to identify and test for association of
haplotypes in CATHGEN. HaploStats expands on the likelihood
approach to account for ambiguity in case-control studies by using a
generalized linear model to test for haplotype association, which
allows for adjustment of nongenetic covariates [70]. This method
derives a score statistic to test the null hypothesis of no association of
the trait with the genotype. In addition to the global statistic,
HaploStats computes score statistics for the components of the
genetic vectors, such as individual haplotypes. The software MERLIN
(Multipoint Engine for Rapid Likelihood Inference) was used for two-
point and multipoint nonparametric linkage analysis [71].
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